Zejula and Middle insomnia - a phase IV clinical study of FDA data

Summary:

Middle insomnia is reported as a side effect among people who take Zejula (niraparib tosylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zofran, and have Ovarian cancer.

The phase IV clinical study analyzes which people have Middle insomnia when taking Zejula. It is created by eHealthMe based on reports of 22,010 people who have side effects when taking Zejula from the FDA, and is updated regularly.

What is Zejula?

Zejula has active ingredients of niraparib tosylate. eHealthMe is studying from 22,014 Zejula users. Check the latest studies of Zejula.

What is Middle insomnia?

Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night) is found to be associated with 987 drugs and 970 conditions by eHealthMe. Check the latest studies of Middle insomnia.

On Jul, 21, 2026

22,010 people reported to have side effects when taking Zejula.
Among them, 256 people (1.16%) have Middle insomnia.

Among these 256 people:

* Approximation only. Some reports may have incomplete information.

Do you take Zejula and have Middle insomnia?

- Check whether Middle insomnia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zejula:

Zejula (22,014 reports)

Middle insomnia treatments and more:

Middle insomnia (21,952 reports)

How severe was Middle insomnia and when was it recovered:

Middle insomnia in Zejula

Expand to all the drugs that have ingredients of niraparib tosylate:

Middle insomnia and drugs with ingredients of niraparib tosylate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zejula:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Middle insomnia:

Middle insomnia (987 drugs)

Browse all the conditions that are associated with Middle insomnia:

Middle insomnia (970 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on niraparib tosylate (the active ingredients of Zejula) and Zejula (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.